首页>
外国专利>
BIOMARKERS FOR PREDICITING AND ASSESSING RESPONSIVENESS OF THYROID AND KIDNEY CANCER SUBJECTS TO LENVATINIB COMPOUNDS
BIOMARKERS FOR PREDICITING AND ASSESSING RESPONSIVENESS OF THYROID AND KIDNEY CANCER SUBJECTS TO LENVATINIB COMPOUNDS
展开▼
机译:预测和评估甲状腺和肾癌患者对lenvatinib化合物反应的生物标志物
展开▼
页面导航
摘要
著录项
相似文献
摘要
Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.
展开▼